Antivirals for influenza-Like Illness? A randomised Controlled trial of Clinical and Cost effectiveness in primary CarE (ALIC4 E): the ALIC4 E protocol.
- Bongard E The Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
- van der Velden AW Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
- Cook J The Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
- Saville B Berry Consultants, Austin, Texas, USA.
- Beutels P Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium.
- Munck Aabenhus R Institute for Public Health, University of Copenhagen, Copenhagen, Denmark.
- Brugman C Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
- Chlabicz S Department of Family Medicine and Community Nursing, Medical University of Bialystok, Bialystok, Poland.
- Coenen S Centre for General Practice, Department of Primary and Interdisciplinary Care (ELIZA), University of Antwerp, Antwerp, Belgium.
- Colliers A Centre for General Practice, Department of Primary and Interdisciplinary Care (ELIZA), University of Antwerp, Antwerp, Belgium.
- Davies M Ely Bridge Surgery, Ely, UK.
- De Paor M Department of General Practice, Royal College of Surgeons in Ireland School of Medicine, Dublin, Ireland.
- De Sutter A Department of Family Medicine and Primary Health Care, Ghent University, Ghent, Belgium.
- Francis NA Department of Population Medicine, Cardiff University School of Medicine, Cardiff, UK.
- Glinz D University of Basel, Basel, Switzerland.
- Godycki-Ćwirko M Department of Family and Community Medicine, Medical University of Lodz, Lodz, Poland.
- Goossens H Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium.
- Holmes J Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
- Ieven M Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium.
- de Jong M Department of Medical Microbiology, Academic Medical Center, Amsterdam, The Netherlands.
- Lindbaek M Department of General Practice, Institute of Health and Society, University of Oslo, Oslo, Norway.
- Little P Primary Care and Population Science, University of Southampton, Southampton, UK.
- Martinón-Torres F SERGAS, Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela, Spain.
- Moragas A Primary Healthcare Centre Jaume I, Universitat Rovira i Virgili, Tarragona, Catalonia, Spain.
- Pauer J Drug Research Centre LLC, Balatonfüred, Hungary.
- Pfeiferová M Institute of General Practice, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- Radzeviciene-Jurgute R JSC Mano Seimos Gydytojas, Klaipėda, Lithuania.
- Sundvall PD Närhälsan, Research and Development Primary Health Care, Region Västra Götaland, Research and Development Center Södra Älvsborg, Borås, Sweden.
- Torres A Department of Pulmonology, Hospital Clínic de Barcelona, Universitat de Barcelona and IDIBAPS, Barcelona, Spain.
- Touboul P Department of Public Health, University Hospital of Nice, Nice, France.
- Varthalis D Clinic of Social and Family Medicine, University of Crete, Heraklion, Greece.
- Verheij T Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
- Butler CC The Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
- 2018-07-14
Published in:
- BMJ open. - 2018
adaptive clinical trial
cost-benefit analysis
influenza
oseltamivir
primary healthcare
Activities of Daily Living
Antiviral Agents
Cost-Benefit Analysis
Female
Fever
Headache
Hospitalization
Humans
Influenza, Human
Male
Multicenter Studies as Topic
Myalgia
Nonprescription Drugs
Oseltamivir
Pneumonia
Pragmatic Clinical Trials as Topic
Prescription Drugs
Self Care
Symptom Assessment
Time Factors
English
INTRODUCTION
Effective management of seasonal and pandemic influenza is a high priority internationally. Guidelines in many countries recommend antiviral treatment for older people and individuals with comorbidity at increased risk of complications. However, antivirals are not often prescribed in primary care in Europe, partly because its clinical and cost effectiveness has been insufficiently demonstrated by non-industry funded and pragmatic studies.
METHODS AND ANALYSIS
Antivirals for influenza-Like Illness? An rCt of Clinical and Cost effectiveness in primary CarE is a European multinational, multicentre, open-labelled, non-industry funded, pragmatic, adaptive-platform, randomised controlled trial. Initial trial arms will be best usual primary care and best usual primary care plus treatment with oseltamivir for 5 days. We aim to recruit at least 2500 participants ≥1 year presenting with influenza-like illness (ILI), with symptom duration ≤72 hours in primary care over three consecutive periods of confirmed high influenza incidence. Participant outcomes will be followed up to 28 days by diary and telephone. The primary objective is to determine whether adding antiviral treatment to best usual primary care is effective in reducing time to return to usual daily activity with fever, headache and muscle ache reduced to minor severity or less. Secondary objectives include estimating cost-effectiveness, benefits in subgroups according to age (<12, 12-64 and >64 years), severity of symptoms at presentation (low, medium and high), comorbidity (yes/no), duration of symptoms (≤48 hours/>48-72 hours), complications (hospital admission and pneumonia), use of additional prescribed medication including antibiotics, use of over-the-counter medicines and self-management of ILI symptoms.
ETHICS AND DISSEMINATION
Research ethics committee (REC) approval was granted by the NRES Committee South Central (Oxford B) and Clinical Trial Authority (CTA) approval by The Medicines and Healthcare products Regulatory Agency. All participating countries gained national REC and CTA approval as required. Dissemination of results will be through peer-reviewed scientific journals and conference presentations.
TRIAL REGISTRATION NUMBER
ISRCTN27908921; Pre-results.
Effective management of seasonal and pandemic influenza is a high priority internationally. Guidelines in many countries recommend antiviral treatment for older people and individuals with comorbidity at increased risk of complications. However, antivirals are not often prescribed in primary care in Europe, partly because its clinical and cost effectiveness has been insufficiently demonstrated by non-industry funded and pragmatic studies.
METHODS AND ANALYSIS
Antivirals for influenza-Like Illness? An rCt of Clinical and Cost effectiveness in primary CarE is a European multinational, multicentre, open-labelled, non-industry funded, pragmatic, adaptive-platform, randomised controlled trial. Initial trial arms will be best usual primary care and best usual primary care plus treatment with oseltamivir for 5 days. We aim to recruit at least 2500 participants ≥1 year presenting with influenza-like illness (ILI), with symptom duration ≤72 hours in primary care over three consecutive periods of confirmed high influenza incidence. Participant outcomes will be followed up to 28 days by diary and telephone. The primary objective is to determine whether adding antiviral treatment to best usual primary care is effective in reducing time to return to usual daily activity with fever, headache and muscle ache reduced to minor severity or less. Secondary objectives include estimating cost-effectiveness, benefits in subgroups according to age (<12, 12-64 and >64 years), severity of symptoms at presentation (low, medium and high), comorbidity (yes/no), duration of symptoms (≤48 hours/>48-72 hours), complications (hospital admission and pneumonia), use of additional prescribed medication including antibiotics, use of over-the-counter medicines and self-management of ILI symptoms.
ETHICS AND DISSEMINATION
Research ethics committee (REC) approval was granted by the NRES Committee South Central (Oxford B) and Clinical Trial Authority (CTA) approval by The Medicines and Healthcare products Regulatory Agency. All participating countries gained national REC and CTA approval as required. Dissemination of results will be through peer-reviewed scientific journals and conference presentations.
TRIAL REGISTRATION NUMBER
ISRCTN27908921; Pre-results.
- Language
-
- English
- Open access status
- gold
- Identifiers
-
- DOI 10.1136/bmjopen-2017-021032
- PMID 30002007
- Persistent URL
- https://sonar.ch/global/documents/232332
Statistics
Document views: 30
File downloads:
- Full-text: 0